Welcome to our dedicated page for Portage Biotech SEC filings (Ticker: PRTG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PRTG SEC filings page on Stock Titan aggregates regulatory documents originally filed as Portage Biotech Inc. and, following its name change, as AlphaTON Capital Corp. The company is a foreign private issuer formed under the laws of the British Virgin Islands and files annual reports on Form 20-F and current reports on Form 6-K. These filings trace the evolution from a clinical-stage immuno-oncology company to an issuer with two primary business lines: a legacy oncology R&D portfolio and a digital asset treasury strategy focused on The Open Network (TON) token.
For investors analyzing the legacy PRTG listing, Form 6-K reports and accompanying exhibits provide details on clinical and preclinical programs, including PORT-6 and PORT-7, as well as financial statements, operating expenses, and research and development trends. Other filings describe capital-raising activities such as private placements of ordinary shares and pre-funded warrants, at-the-market offering agreements under an effective Form F-3 shelf registration statement, and related legal opinions and placement agent agreements.
More recent 6-K filings under the AlphaTON Capital Corp name outline the company’s TON-focused strategy, including a private placement offering funded with cash and cryptocurrency, a loan agreement with a digital asset lender, and a treasury management agreement for TON holdings. These documents explain how net proceeds are expected to be allocated between cryptocurrency acquisitions and the legacy immune-oncology business, and they describe associated registration rights and lock-up arrangements.
On Stock Titan, SEC filings linked to the historical PRTG symbol are updated in near real time from EDGAR and can be paired with AI-powered summaries that highlight key terms, business descriptions, financing structures, and risk disclosures. This helps readers quickly understand how the company’s strategy, capital structure, and even its name and ticker have changed, while still allowing access to the full original filings for detailed review.
Portage Biotech has successfully regained compliance with Nasdaq Capital Market's minimum stockholders' equity requirement, as announced in a Form 6-K filed on June 28, 2025. The company received official notice from Nasdaq on June 24, 2025, confirming their compliance status and closing the previously announced listing matter.
Key points from the filing:
- Filing incorporates by reference into Form S-8 (File No. 333-275842) and Form F-3 (File No. 333-286961) registration statements
- Company maintains its listing on the Nasdaq Capital Market
- Press release dated June 25, 2025, included as Exhibit 99.1
- Document signed by CFO Andrea Park
This development is significant for investors as it confirms Portage Biotech's continued compliance with Nasdaq listing requirements, ensuring maintained access to public markets and investor visibility.